Learn About Neurotoxicity Syndromes

What is the definition of Neurotoxicity Syndromes?
Neurotoxicity syndromes is a term used to describe neurological disorders caused by exposure to toxic substances. Neurotoxicity may occur after exposure to substances such as drugs; chemotherapy; radiation; heavy metals, such as lead or mercury; pesticides; industrial and/or cleaning solvents; petroleum-based products and dispersants; some foods and food additives; and some naturally occurring environmental substances. Exposure to such toxic substances disrupts or kills nerve cells, or neurons, that are responsible for brain and nervous system functions. Neurotoxicity may occur by exposure to toxic substances through ingestion, injection, inhalation, spray, direct skin exposure, or other methods.
Save information for later
Sign Up
What are the symptoms of Neurotoxicity Syndromes?
Symptoms of neurotoxicity may be immediate or delayed. Symptoms of neurotoxicity can include weakness, numbness, headache, memory loss, visual disturbances, cognitive difficulties, behavioral changes, and loss of sexual function, among others.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neurotoxicity Syndromes?
Treatment for neurotoxicity includes stopping any exposure to the toxic substance and supportive therapy to treat the associated symptoms.
Who are the top Neurotoxicity Syndromes Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Neurotoxicity Syndromes Clinical Trials?
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Summary: This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL). Relapsed NHL is the condition of returned Non-Hodgkin lymphoma. Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma. Cyt...

What are the Latest Advances for Neurotoxicity Syndromes?
Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Dasatinib for treatment of CAR T-cell therapy-related complications.
Tired of the same old research?
Check Latest Advances
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT).